Qualcomm, Novartis To Invest In Mobile Health, Aggregate Trial Data
This article was originally published in The Gray Sheet
Executive Summary
The companies say they are partnering to invest in start-ups that have potential to change healthcare delivery and are using Qualcomm’s 2net Platform in a clinical trial to aggregate patient data and personalize treatments.
You may also be interested in...
Big Tech Firms Target Health Care Space With Cheap Sensors In Smartphones
Recent activities by three smartphone giants point to a potential future where the phone itself more frequently serves as a monitoring or diagnosing device, in place of external sensors. If the trend rolls on, it could have important implications for the mobile health sector.
Digital Health Briefs: Post-Surgery Remote Monitoring; NHS England Technology Funding; Qualcomm Product
Study finds remote monitoring can assess patient mobility and correlates with length of stay. NHS England boosts technology fund by 250 million pounds. Qualcomm introduces 2net Mobile. More digital news.
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.